|
Home
What is
Hepatitis
How is it
Transmitted
Long Term
Prognosis
Complications of
HCV
Liver
Biopsy
Treatment Info
(Interferon, Herbal, etc)
Lab Tests (PCR,
Genotype,etc.)
Nutrition
& Alternative Info
Patient
Information (Support Groups, Doctor Listing,
etc)
Related
Webpages
Transplant
Info
Site
Search
HCV
Webrings
My
guestbookbook
Site
Awards
FAQ &
Disclaimers
|
Am J Clin Pathol 2000 Jan;113(1):35-9
Increased hepatic iron deposition resulting from treatment of
chronic hepatitis C with ribavirin.
Fiel MI, Schiano TD, Guido M, Thung SN, Lindsay KL, Davis GL, Lewis
JH, Seeff LB, Bodenheimer HC Jr, Lillian and Henry M. Stratton-Hans
Popper Department of Pathology, Mount Sinai Medical Center, City
University of New York, NY 10029, USA. [Medline record in
process]
Increased levels of hepatic iron may impair the response of
patients with chronic hepatitis C to treatment with
interferon-alfa, but combination therapy with ribavirin has
demonstrated efficacy in the treatment of hepatitis C. When used
alone or with interferon-alfa, ribavirin may cause a dose-dependent
reversible hemolytic anemia. We compared the extent and cellular
localization of iron deposition in liver tissue from biopsy
specimens obtained before and after 36 weeks of therapy with
ribavirin or placebo for 59 patients with chronic hepatitis C.
Paired slides were available for review from 26 ribavirin and 27
placebo recipients. Iron deposition was assessed using coded slides
stained with Perls Prussian blue and was semiquantitated in
hepatocytes, Kupffer cells, and areas of fibrosis. The overall iron
score fell by 0.96 in the placebo group and increased 1.69 in the
ribavirin recipients. Iron was deposited mainly in hepatocytes; the
hepatocyte iron score increased from 2.19 to 3.81 in the ribavirin
group. The amount of iron staining in Kupffer cells declined in the
placebo group and increased slightly in the ribavirin group. Iron
changes in areas of fibrosis were minor and did not differ between
groups. Increased total hepatic iron deposition occurred during a
9-month course of ribavirin. Ribavirin-associated hemolysis
deposits iron preferentially in hepatocytes. This increased
deposition of hepatic iron does not seem to affect the biochemical
or histologic response to ribavirin therapy but may have
implications for hepatocyte susceptibility to future injury.
PMID: 10631856, UI: 20097474
Home | What is HCV | Transmission |
Future |
Complications |
Biopsy |
Treatment
| Lab |
Nutrition |
Patient |
Links | Transplant |
Webrings |
guestbookbook |
Awards |
FAQ
|
|